The phrase “COVID-19” is mirrored in a drop on a syringe needle on this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration
Oct 19 (Reuters) – A mid-stage trial testing Atea Prescription drugs’ (AVIR.O) COVID-19 therapy failed to satisfy the primary purpose of decreasing the quantity of SARS-CoV-2 virus in non-hospitalized sufferers with gentle or reasonable illness, the corporate mentioned on Tuesday.
Atea’s shares slumped 70.9% to $11.78 in premarket buying and selling.
The corporate is creating the oral drug, AT-527, in partnership with Roche (ROG.S) and each the businesses are collaborating on a number of research of the drug for the therapy of COVID-19.
Within the mid-stage research, AT-527 didn’t present a transparent discount in SARS-CoV-2 viral load within the general inhabitants of sufferers with gentle or reasonable COVID-19 in comparison with placebo, nevertheless it confirmed a discount in viral load in high-risk sufferers with underlying well being circumstances.
Many elements together with completely different variants rising through the research, larger penetration of vaccinations throughout the enrolled inhabitants might have impacted outcomes, it mentioned.
Atea mentioned based mostly on the most recent outcomes and the evolving COVID-19 setting, it’s modifying an ongoing late-stage research testing the drug in non-hospitalized sufferers with gentle to reasonable COVID-19 to incorporate adjustments to the trial’s essential purpose and affected person inhabitants.
Because of this, the corporate now expects late-stage trial knowledge within the second half of 2022, as an alternative of the latter half of this yr.
Reporting by Mrinalika Roy in Bengaluru; Enhancing by Shailesh Kuber
Our Requirements: The Thomson Reuters Trust Principles.
0 Comments